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Background: Over the last few decades, esophageal cancer incidence and mortality trends varied substantially across
Europe, with important differences between sexes and the two main histological subtypes, squamous cell carcinoma
(ESCC) and adenocarcinoma (EAC).
Patients and methods: To monitor recent esophageal cancer mortality trends and to compute short-term predictions
in the European Union (EU) and selected European countries, we analyzed data provided by the World Health
Organization (WHO) for 1980–2011. We also analyzed incidence trends and relative weights of ESCC and EAC across
Europe using data from Cancer Incidence in Five Continents.
Results: Long-term decreasing trends were observed for male esophageal cancer mortality in several southern and
western European countries, whereas in central Europe mortality increased until the mid-1990s and started to stabilize
or decline over the last years. In some eastern and northern countries, the rates were still increasing. Mortality among
European women remained comparatively low and showed stable or decreasing trends in most countries. Between
2000–2004 and 2005–2009, esophageal cancer mortality declined by 7% (from 5.34 to 4.99/100 000) in EU men, and
by 3% (from 1.12 to 1.09/100 000) in EU women. Predictions to 2015 show persistent declines in mortality rates for
men in the EU overall, and stable rates for EU women, with rates for 2015 of 4.5/100 000 men (about 22 300 deaths)
and 1.1/100 000 women (about 7400 deaths). In northern Europe, EAC is now the predominant histological type
among men, while for European women ESCC is more common and corresponding rates are still increasing in several
countries.
Conclusion(s): The observed trends reﬂect the variations in alcohol drinking, tobacco smoking and overweight across
European countries.
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introduction
Esophageal cancer incidence and mortality trends varied sub-
stantially across Europe over the last few decades, with import-
ant differences between sexes and the two main histological
subtypes, squamous cell carcinoma (ESCC) and adenocarcin-
oma (EAC) [1].
Among men, there were marked long-term declines in mor-
tality in southern European countries such as France and Italy,
whereas upward trends were observed up to the most recent
years in the UK, the Netherlands and Romania [1]. In the
European Union (EU) as a whole, male age-standardized mor-
tality rates decreased between 1990–1994 and 2000–2004 from
5.7 to 5.4/100 000, while female rates remained stable around
1.1/100 000 [2].
ESCC was the main histological type in most European coun-
tries, though steady increases in EAC incidence were observed
in several regions. In the late 1990s, EAC was already more fre-
quent than ESCC in some northern European countries, such as
Denmark and Scotland [1].
To monitor recent mortality trends and to compute short-
term predictions of esophageal cancer mortality rates in the EU
and selected European countries, we analyzed mortality data
provided by the World Health Organization (WHO). We also
analyzed the trends in incidence rates of ESCC and EAC and the
relative weight of these main histological types of esophageal
cancer across Europe.
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Figure 1. Joinpoint analysis for age-standardized (world population) mortality rates per 100 000 men for esophageal cancer (all ages and truncated at 25–49
and 35–64 years) in selected European countries, 1980–2011.□–□, all ages;○– –○, 25–49 years; ▵–▵, 35–64 years.
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methods
Ofﬁcial data for esophageal cancer mortality in the EU and selected
European countries over the period 1980–2011, and the corresponding
population ﬁgures, were derived from the WHO database [3]. Since in the
period considered three different Revisions of the International
Classiﬁcation of Diseases (ICDs) were used to classify esophageal cancer
deaths, death certiﬁcation numbers corresponding to codes A046 (ICD-8)
[4], B090 (ICD-9) [5] and C15 (ICD-10) [6] were extracted, as applicable.
Country- and sex-speciﬁc mortality rates were computed for each 5-year age
group (0–4,…, 75–79, 80+) and calendar year, and age-standardized rates
were calculated at all ages and truncated at 25–49 and 35–64 years (direct
method, world population). Mortality rates for the EU as a whole were com-
puted using the aggregated number of deaths, and corresponding popula-
tions, in its 27 Member States, as deﬁned in January 2007; Cyprus was
excluded due to limited data available.
Poisson regression analysis was carried out using the Joinpoint software
[7] in order to identify signiﬁcant changes in the mortality trends, allowing
for up to three joinpoints.
For selected European countries and the EU as a whole, we provided pre-
dicted numbers of esophageal cancer deaths and rates for the year 2015.
These were derived by ﬁtting a joinpoint model to each 5-year age-speciﬁc
(age groups 0–4,…, 75–79, 80+) number of certiﬁed deaths, assuming a
Poisson distribution, to identify the most recent trend segment. Then, a
linear regression was carried out on mortality data for each age group over
the most recent trend provided by the joinpoint model, to compute the pre-
dicted age-speciﬁc number of deaths, the corresponding 95% conﬁdence
intervals (CIs) and prediction intervals (PIs) [8]. Population ﬁgures for 2015
were obtained from EUROSTAT [9].
Incidence data were obtained from the Cancer Incidence in Five
Continents (CI5) databases [10, 11] and analyzed by histological type. For
countries with more than one cancer registry, data were aggregated to ensure
the highest geographic coverage and the analyses were restricted to the
longest common calendar period between registries.
Annual data for the period 1980–2002 (the last available year) were
derived from the CI5-plus database [10], and 3-year moving averages were
used to represent the histology- and sex-speciﬁc incidence trends in age-
standardized incidence rates (direct method, world standard population).
Grouped incidence data, referring mostly to the period 1998–2002, pro-
vided by CI5 volume IX (CI5-IX) [11] were also retrieved, and used to
describe the geographical distribution of esophageal cancer histological
types across Europe, using ArcGIS [12].
results
In the EU as a whole, male esophageal mortality rates decreased
since the early 1990s (all ages: APC =−1.2% in 1994–2009)
with steeper declines since the early 2000s in younger age
groups. Decreases in overall male mortality trends were
observed in France, Greece, Italy, Portugal and Switzerland.
Over the most recent calendar years, trends have also been de-
creasing or leveling off in the Czech Republic, Germany,
Hungary, Ireland, Poland, the Russian Federation, Spain,
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Figure 2. Joinpoint analysis for age-standardized (world population) mortality rates per 100 000 women for esophageal cancer (all ages and truncated at
25–49 and 35–64 years) in selected European countries, 1980–2011.□–□, all ages;○–○, 25–49 years; ▵–▵, 35–64 years.
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Ukraine and the UK, whereas increasing trends were still
observed in Latvia, Lithuania, the Netherlands, Norway and
Romania (Figure 1 and supplementary Table S1, available at
Annals of Oncology online).
Among EU women, esophageal cancer mortality started to
decline in the mid-1990s at all ages (APC = −0.6 in 1995–
2009) and in the age group 25–49 years (APC = −2.9 in 1996–
2009), while for the 35–64 year age group a slight upward
trend was observed over the period 1980–2009 (APC = 0.5%).
Long-term decreasing trends were observed for overall female
mortality in Italy, Poland, Portugal, the Russian Federation
and Ukraine, and more recent declines (since the mid/late
1990s) were observed in Hungary and in the UK, whereas in
Germany, the Netherlands and Spain increasing mortality
trends were still observed over the most recent calendar years
(Figure 2 and supplementary Table S1, available at Annals of
Oncology online).
Between 2000–2004 and 2005–2009, in the EU as a whole,
esophageal cancer mortality fell by 7% at all ages among men
(from 5.34 to 4.99/100 000) and by 3% among women (from
1.12 to 1.09/100 000). The UK, particularly Scotland, had the
highest overall mortality rate in 2005–2009 for both sexes,
whereas Greece showed the lowest one among men (1.38/
100 000) (Tables 1 and 2).
Table 1. Age-standardized (world population) mortality rates from esophageal cancer per 100 000 men (at all ages and truncated at 25–49 and 35–64
years) in selected European countries and in the European Union (EU) in the periods 2000–2004 and 2005–2009 (unless otherwise mentioned in
parenthesis), and corresponding percent changes
All ages 25–49 years 35–64 years
2000–2004 2005–2009 % change 2000–2004 2005–2009 % change 2000–2004 2005–2009 % change
Austria 3.81 3.88 2 1.24 1.03 −17 6.81 6.96 2
Belarus (2000–2003/2007–2009) 5.27 5.59 6 1.57 1.55 −1 10.57 11.15 5
Belgium (2003–2004) 5.47 5.20 −5 1.74 1.44 −17 9.01 8.64 −4
Bulgaria 1.99 2.43 22 0.79 0.98 24 3.89 4.78 23
Croatia 5.35 5.02 −6 1.84 1.39 −24 9.60 9.40 −2
Czech Republic 4.74 4.48 −5 1.90 1.38 −27 9.24 8.51 −8
Denmark 6.44 5.39 −16 1.63 0.93 −43 9.64 7.34 −24
Estonia 4.67 5.22 12 1.16 1.17 1 8.63 9.84 14
Finland 2.90 2.92 1 0.51 0.48 −6 4.46 4.67 5
France 7.19 5.99 −17 2.46 1.46 −41 12.58 10.24 −19
Germany 4.94 4.80 −3 1.57 1.30 −17 8.97 8.21 −8
Greece 1.49 1.38 −7 0.42 0.40 −5 2.08 2.09 0
Hungary 8.28 7.08 −14 4.55 3.00 −34 19.32 15.77 −18
Iceland 3.76 5.28 40 1.13 0.66 −42 4.52 6.72 49
Ireland 7.62 7.36 −3 1.96 1.57 −20 9.51 8.79 −8
Italy (2000–2003/2006–2009) 2.87 2.22 −23 0.66 0.52 −21 4.27 3.37 −21
Latvia 5.47 5.79 6 1.83 1.31 −28 10.72 11.17 4
Lithuania 6.35 6.85 8 1.89 2.03 7 12.60 14.14 12
Luxembourg 4.99 5.21 4 1.70 1.15 −32 8.51 8.97 5
Macedonia 1.75 1.67 −5 0.88 0.61 −31 3.10 2.85 −8
Malta 2.41 3.24 34 0.76 0.53 −30 4.20 3.58 −15
The Netherlands 7.13 7.71 8 1.64 1.49 −9 10.44 10.88 4
Norway 3.01 3.23 7 0.49 0.57 16 3.64 4.22 16
Poland 4.92 4.40 −11 1.43 1.14 −20 9.16 7.79 −15
Portugal 5.51 5.35 −3 3.29 2.99 −9 10.94 10.95 0
Republic of Moldova 3.06 3.14 3 1.04 0.64 −38 6.02 5.66 −6
Romania 3.01 3.57 19 1.44 1.48 3 6.54 7.79 19
Russian Federation 6.57 6.07 −8 1.45 1.16 −20 11.54 10.53 −9
Slovakia 7.23 6.48 −10 3.68 2.17 −41 15.43 13.69 −11
Slovenia 4.91 4.40 −10 2.05 1.13 −45 8.17 7.51 −8
Spain 4.82 4.13 −14 1.66 1.21 −27 8.88 7.26 −18
Sweden 3.09 3.08 −0 0.52 0.55 6 4.24 4.26 0
Switzerland 4.83 4.56 −6 1.04 0.72 −31 7.28 6.67 −8
Ukraine (2005–2006, 2008–2009) 4.85 4.45 −8 1.62 1.34 −17 9.99 9.44 −6
UK 8.71 8.71 0 1.92 1.74 −9 11.67 11.57 −1
UK, England and Wales 8.53 8.54 0 1.86 1.71 −8 11.35 11.25 −1
UK, Northern Ireland 7.80 8.28 6 2.62 1.83 −30 10.93 12.14 11
UK, Scotland 10.93 10.63 −3 2.33 2.02 −13 15.16 14.61 −4
EU (27) 5.34 4.99 −7 1.68 1.30 −23 9.03 8.25 −9
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Persisting favorable trends in overall male esophageal cancer
mortality rates are predicted up to 2015 (Figure 3): in the EU,
the predicted age-standardized mortality rate is 4.46/100 000,
corresponding to ∼22 300 esophageal cancer deaths. The pre-
dicted rates are 4.24/100 000 for France, 4.17/100 000 for
Germany, 1.67/100 000 for Italy, 3.14/100 000 for Poland,
3.52/100 000 for Spain and 8.51/100 000 for the UK. Among
EU women, the predicted age-standardized mortality rate is
1.07/100 000, corresponding to ∼7400 esophageal cancer
deaths.
Among men (Figure 4), increasing EAC incidence trends
were observed in most countries, while ESCC trends have been
decreasing or stabilizing over the last few decades. In Denmark,
the Netherlands, England and Scotland, the increases in male
EAC trends were among the steepest observed, and the EAC in-
cidence is now higher than that of the ESCC. In central and
southern Europe, smaller rises in EAC were observed and ESCC
remains the predominant histological type among men.
Trends were less stable among women (supplementary
Figure S1, available at Annals of Oncology online), as very low
histology-speciﬁc incidence rates were observed. ESCC was the
predominant histological type among women in all registration
areas considered and still presented increasing trends in Austria,
Denmark, Estonia, Slovakia and Switzerland.
Table 2. Age-standardized (world population) mortality rates from esophageal cancer per 100 000 women (at all ages and truncated at 25–49 and
35–64 years) in selected European countries and in the European Union (EU) in the periods 2000–2004 and 2005–2009 (unless otherwise mentioned
in parenthesis), and corresponding percent changes
All ages 25–49 years 35–64 years
2000–2004 2005–2009 % change 2000–2004 2005–2009 % change 2000–2004 2005–2009 % change
Austria 0.65 0.61 −6 0.16 0.09 −44 1.02 0.93 −9
Belarus (2000–2003/2007–2009) 0.35 0.30 −14 0.14 0.08 −43 0.44 0.38 −14
Belgium (2003–2004) 1.46 1.32 −10 0.42 0.19 −55 2.47 1.93 −22
Bulgaria 0.48 0.39 −19 0.23 0.13 −43 0.70 0.62 −11
Croatia 0.64 0.61 −5 0.21 0.11 −48 0.84 0.71 −15
Czech Republic 0.60 0.64 7 0.24 0.10 −58 0.93 1.06 14
Denmark 1.91 1.71 −10 0.49 0.29 −41 2.49 2.40 −4
Estonia 0.48 0.43 −10 0.07 0.16 129 0.56 0.71 27
Finland 0.87 0.97 11 0.06 0.08 33 0.77 1.08 40
France 1.01 0.98 −3 0.34 0.24 −29 1.57 1.53 −3
Germany 1.00 1.04 4 0.25 0.23 −8 1.65 1.67 1
Greece 0.31 0.27 −13 0.09 0.07 −22 0.30 0.23 −23
Hungary 1.17 0.96 −18 0.64 0.45 −30 2.58 2.16 −16
Iceland 1.07 1.22 14 0.00 0.00 . 0.38 0.77 103
Ireland 3.16 2.84 −10 0.45 0.37 −18 3.14 2.57 −18
Italy (2000–2003/2006–2009) 0.56 0.47 −16 0.12 0.12 0 0.71 0.62 −13
Latvia 0.44 0.59 34 0.09 0.04 −56 0.62 0.88 42
Lithuania 0.50 0.65 30 0.15 0.28 87 0.74 1.15 55
Luxembourg 0.98 1.02 4 0.00 0.21 . 0.69 1.90 175
Macedonia 0.42 0.25 −40 0.10 0.05 −50 0.64 0.31 −52
Malta 0.41 0.84 105 0.00 0.00 . 0.41 0.73 78
The Netherlands 2.09 2.17 4 0.47 0.35 −26 2.83 2.91 3
Norway 0.86 0.81 −6 0.17 0.05 −71 1.14 1.13 −1
Poland 0.74 0.75 1 0.20 0.17 −15 1.08 1.15 6
Portugal 0.72 0.55 −24 0.15 0.13 −13 0.73 0.54 −26
Republic of Moldova 0.43 0.34 −21 0.16 0.11 −31 0.68 0.54 −21
Romania 0.41 0.46 12 0.17 0.17 0 0.60 0.81 35
Russian Federation 0.99 0.84 −15 0.19 0.17 −11 1.01 0.95 −6
Slovakia 0.62 0.59 −5 0.35 0.20 −43 1.15 0.98 −15
Slovenia 0.67 0.59 −12 0.10 0.10 0 0.52 1.00 92
Spain 0.47 0.48 2 0.21 0.16 −24 0.72 0.78 8
Sweden 0.94 0.89 −5 0.25 0.10 −60 1.16 1.14 −2
Switzerland 1.03 1.13 10 0.21 0.15 −29 1.44 1.52 6
Ukraine (2005–2006, 2008–2009) 0.39 0.31 −21 0.09 0.10 11 0.48 0.47 −2
UK 3.20 3.04 −5 0.49 0.46 −6 3.26 3.26 0
UK, England and Wales 3.12 2.96 −5 0.50 0.46 −8 3.20 3.20 0
UK, Northern Ireland 2.84 2.69 −5 0.30 0.37 23 2.92 3.06 5
UK, Scotland 4.04 3.97 −2 0.52 0.52 0 3.99 3.90 −2
EU (27) 1.12 1.09 −3 0.28 0.22 −21 1.51 1.51 0
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Among men, most countries in northern and western Europe
showed a higher proportion of EAC than any other histological
type and presented the lowest values of the ESCC/EAC ratio,
whereas in southern, central/eastern Europe the proportions of
ESCC were generally higher (supplementary Figure S2 and
Table S2, available at Annals of Oncology online). Among
women (supplementary Figure S3 and Table S2, available at
Annals of Oncology online), the proportion of ESCC incident
cases was higher than that of EAC in all large countries. Central
and eastern European countries showed the highest proportions
of unspeciﬁed esophageal cancers in both sexes.
discussion
This updated analysis of esophageal cancer mortality trends in
Europe conﬁrms the long-term downward mortality rates
observed for male esophageal cancer in several western coun-
tries, while in central European countries mortality trends were
upwards until mid-1990s and started to stabilize or decline only
over recent years. However, in some eastern and northern coun-
tries, male esophageal cancer mortality is still increasing.
Mortality rates among European women remained comparatively
low and showed stable or decreasing trends in some countries.
Regarding incidence, the EAC rates rose substantially among
men in northern Europe and surpassed ESCC ones over the last
decade, whereas ESCC remains the predominant histological
type among European women and rates are still increasing in
several countries. Such trends are unlikely to be attributable to a
better classiﬁcation of cases, as the unspeciﬁed esophageal
cancer rates were low and did not appreciably decline in those
countries. However, incidence trends must be interpreted with
caution, since in some European countries incidence data had
only a limited coverage of population.
Improvements in disease management may have somewhat
inﬂuenced esophageal cancer mortality, as some increase in rela-
tive survival has been observed across Europe in the last few
decades [13]. However, the heterogeneity in esophageal cancer
incidence and mortality trends mostly reﬂects the differences in
the exposure to the main determinants of EAC and ESCC
cancer and their variations with time and across populations.
Alcohol consumption is associated with an increased risk of
ESCC [14] but not of EAC [15], whereas tobacco smoking is a
risk factor for both ESCC and EAC, the association being,
however, stronger for ESCC [16, 17]. EAC is also associated with
overweight/obesity and gastro-esophageal reﬂux disease [18],
and it is inversely related to Helicobacter pylori infection [19].
Dietary aspects (i.e., low consumption of fruit and vegetables
and high intake of meat, saturated fats and reﬁned carbohy-
drates) are also related to esophageal cancer risk [20], and a
non-negligible fraction of incident cases may be attributable to
these factors [21, 22].
Trends and patterns in alcohol consumption have been
largely heterogeneous across Europe, with widely debated rises
in several Nordic and central European countries, Russia and
the UK, and not so widely appreciated decreases in southern
European countries [23]. Favorable trends observed in male
mortality rates in countries from southern Europe followed
the steady fall in alcohol consumption over the last few decades
[23, 24], similarly to what has been observed for oral and
pharyngeal cancers [25, 26]. Such favorable trends may also be due
to changes in the composition of alcoholic beverages, including a
reduction in acetaldehyde levels in most of these countries [27].
ESCC rates reﬂected the trends in alcohol consumption, decreasing
in southern countries (e.g., France, Italy and Spain), and stabilizing
in northern countries (e.g., Denmark and the UK), while EAC fol-
lowed more consistently the trends in overweight/obesity, with
more appreciable increases in northern Europe than in southern
countries [28, 29].
Tobacco consumption has steadily declined in men from
most European countries over the last few decades. However,
changes in smoking have been less notable than those in
alcohol drinking in southern Europe. Furthermore, alcohol
and tobacco have a synergistic effect on esophageal cancer risk
and the relative risks for combined exposures are one or two
orders of magnitude greater than that of nonsmokers and
nondrinkers [30]. Thus, limitation of one of these factors
leads to the avoidance of a substantial proportion of cases on a
population level [21].
Esophageal cancer trends in women are more difﬁcult to in-
terpret in terms of changes in exposure to risk factors, also on
account of their much lower rates. Still, EAC was proportionally
much less common than ESCC in women compared with men.
This has long been recognized, but it is still surprising given that
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Figure 3. Trends in age-standardized (world population) mortality rates
per 100 000 men for esophageal cancer in the European Union (EU) as a
whole and selected European countries from 1980 to 2011, and predicted
rates for 2015.
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women drink and smoke less than men. A possible explanation
is the lower frequency of abdominal obesity in women, with
consequently less gastro-esophageal reﬂux [31]. Another reason
may be that women use less frequently tight belts and wear
dresses [32].
In conclusion, esophageal cancer mortality has been stabiliz-
ing or decreasing in most European countries, and it is expected
to decrease further in the next few years. Among men, EAC is
now the predominant histological type in northern countries,
while ESCC remains the most common subtype in women.
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Figure 4. Trends in age-standardized (world population) incidence rates per 100 000 men for esophageal cancer by histological types in selected European
countries, 1980–2002.—esophageal squamous cell carcinoma;— esophageal adenocarcinoma;—unspeciﬁed esophageal cancers;—other esophageal cancers.
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